資料來源：https://www.prnewswire.com/news-releases/icad-to-showcase-powerlook-tomo-detection-technology-at-sbiacr-breast-imaging-symposium-300435732.html

iCAD (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced the Company will highlight PowerLook® Tomo Detection, an innovative, concurrent-read computer aided detection solution for digital breast tomosynthesis that can save radiologists valuable reading time without compromising clinical performance, at its booth #300 at the SBI/ACR Breast Imaging Symposium from April 6-9, 2017 in Los Angeles, California. PowerLook Tomo Detection received Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) on March 24, 2017 and is the latest innovation available on the PowerLook® Breast Health Solutions platform.

"Following the recent approval from the FDA, our team is well positioned to bring this innovative cancer detection solution to radiologists across the country, helping them optimize productivity and efficiency without compromising reader performance," said Ken Ferry, CEO of iCAD. "PowerLook Tomo Detection is built on the latest deep learning technology that enables the solution to achieve very high detection accuracy."

In each exam, 2D digital mammography typically produces four images while digital breast 3D tomosynthesis (DBT) can produce hundreds. With DBT, radiologists must spend significantly more time to review and interpret each exam. PowerLook Tomo Detection automatically analyzes each tomosynthesis plane, helping radiologists identify suspicious areas with greater speed and precision. The suspicious areas identified by PowerLook Tomo Detection are blended onto a 2D synthetic image, creating a single enhanced image. The process allows radiologists to navigate the large tomosynthesis data set more efficiently.

"Since we launched PowerLook Tomo Detection in the E.U. in April 2016, multiple high-volume medical facilities have adopted the technology," added Ferry. "Following our FDA approval, we anticipate that many leading healthcare facilities in the U.S. will also recognize the clinical and patient benefits our technology offers. We believe this technology will establish a new standard for how computers and artificial intelligence assist radiologists in detecting breast cancer."

PowerLook Tomo Detection is currently approved for use with GE Healthcare's digital breast tomosynthesis.  The full suite of PowerLook Breast Health Solutions will be on display during the SBI/ACR Breast Imaging Symposium.

About iCAD, Inc.

iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers.